| 43.28 0.26 (0.6%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 60.75 | 1-year : | 67.6 |
| Resists | First : | 52.01 | Second : | 57.88 |
| Pivot price | 46.99  |
|||
| Supports | First : | 42.52 | Second : | 35.37 |
| MAs | MA(5) : | 45.37 |
MA(20) : | 48.14 |
| MA(100) : | 37.83  |
MA(250) : | 34.91 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 16.5 |
D(3) : | 21.6 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 57.88 | Low : | 23.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TWST ] has closed above bottom band by 0.3%. Bollinger Bands are 9.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 44.89 - 45.11 | 45.11 - 45.3 |
| Low: | 42.17 - 42.42 | 42.42 - 42.63 |
| Close: | 42.91 - 43.29 | 43.29 - 43.62 |
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Sun, 15 Mar 2026
Twist Bioscience Corporation $TWST Shares Acquired by EdgePoint Investment Group Inc. - MarketBeat
Sat, 14 Mar 2026
Prosight Management LP Buys New Holdings in Twist Bioscience Corporation $TWST - MarketBeat
Fri, 13 Mar 2026
Twist Bioscience rises on licensing deal for antibody discovery platform - MSN
Wed, 11 Mar 2026
TWST: Automation, AI-driven discovery, and new products fuel growth and margin expansion - TradingView
Wed, 11 Mar 2026
Twist Bioscience Stock Down 6.1% in One Day, Now Is Not The Time To Buy The Stock - Trefis
Tue, 10 Mar 2026
Tax-related share sale by Twist Bioscience (TWST) accounting chief disclosed - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 61 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 121.9 (%) |
| Shares Short | 13,010 (K) |
| Shares Short P.Month | 12,500 (K) |
| EPS | -1.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.44 |
| Profit Margin | -19.6 % |
| Operating Margin | -31.8 % |
| Return on Assets (ttm) | -13.5 % |
| Return on Equity (ttm) | -16.8 % |
| Qtrly Rev. Growth | 16.8 % |
| Gross Profit (p.s.) | 3.29 |
| Sales Per Share | 6.38 |
| EBITDA (p.s.) | -1.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -34.08 |
| PEG Ratio | 0 |
| Price to Book value | 5.81 |
| Price to Sales | 6.77 |
| Price to Cash Flow | -52.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|